MAB1181

antibody from R&D Systems

Targeting: IL18RAP AcPL, CD218b

Western blot (Data presented on provider website)

Blocking/Neutralizing (Supportive data in Antibodypedia)

Antibody Data

Product number

MAB1181

Provider

R&D Systems

Product name

Human IL-18 R beta/IL-1 R7 Antibody

Antibody type

Monoclonal

Description

Protein A or G purified from hybridoma culture supernatant. Detects human IL-18 R beta/IL-1 R7 in direct ELISAs and Western blots. In direct ELISAs and Western blots, less than 1% cross-reactivity with recombinant mouse IL-18 R beta , recombinant human (rh) IL-18 R, rhIL-1 RI, rhIL-1 RII, rhIL-1 RAcP, and rhIL-1 Rrp2 is observed.

Reactivity

Human

Host

Mouse

Conjugate

Unconjugated

Antigen sequence

O95256


Isotype

IgG

Antibody clone number

132016

Vial size

500 ug

Concentration

LYOPH

Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.

References

Submitted references

The IL18RAP region disease polymorphism decreases IL-18RAP/IL-18R1/IL-1R1 expression and signaling through innate receptor-initiated pathways.

Hedl M, Zheng S, Abraham C
Journal of immunology (Baltimore, Md. : 1950) 2014 Jun 15;192(12):5924-32

---

Soluble interleukin-18 receptor complex is a novel biomarker in rheumatoid arthritis.

Takei S, Hoshino T, Matsunaga K, Sakazaki Y, Sawada M, Oda H, Takenaka S, Imaoka H, Kinoshita T, Honda S, Ida H, Fukuda TA, Aizawa H
Arthritis research & therapy 2011 Mar 24;13(2):R52

---

CD molecules 2006--human cell differentiation molecules.

Zola H, Swart B, Banham A, Barry S, Beare A, Bensussan A, Boumsell L, D Buckley C, Bühring HJ, Clark G, Engel P, Fox D, Jin BQ, Macardle PJ, Malavasi F, Mason D, Stockinger H, Yang X
Journal of immunological methods 2007 Jan 30;319(1-2):1-5

---

IL-18 receptor beta-induced changes in the presentation of IL-18 binding sites affect ligand binding and signal transduction.

Wu C, Sakorafas P, Miller R, McCarthy D, Scesney S, Dixon R, Ghayur T
Journal of immunology (Baltimore, Md. : 1950) 2003 Jun 1;170(11):5571-7

---

IL-18 receptor beta-induced changes in the presentation of IL-18 binding sites affect ligand binding and signal transduction.

Wu C, Sakorafas P, Miller R, McCarthy D, Scesney S, Dixon R, Ghayur T
Journal of immunology (Baltimore, Md. : 1950) 2003 Jun 1;170(11):5571-7

Blocking/Neutralizing

Supportive validation

Submitted by

R&D Systems (provider)

Main image

Experimental details

IFN-gamma secretion Induced by IL-18/IL1F4 and Neutralization by Human IL-18 R beta/IL-1 R7 Antibody. In the presence of Recombinant Human TNF-alpha (20 ng/mL, Catalog # 210-TA ), Recombinant Human IL-18/ IL-1F4 stimulates IFN-gamma secretion in the KG-1 human acute myelogenous leukemia cell line in a dose-dependent manner (left-hand graph), as measured by the Human IFN-gamma Quantikine ELISA Kit (Catalog # DIF50). Under these conditions, IFN-gamma secretion elicited by Recombinant Human IL-18/ IL-1F4 (40 ng/mL) is neutralized (right-hand graph) by increasing concentrations of Mouse Anti-Human IL-18 R beta/IL-1 R7 Monoclonal Antibody (Catalog # MAB1181). The ND₅₀ is typically 0.3-1.0 μg/mL.